CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option
Go back to CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option| Merck & Co. (NYSE: MRK) | Delayed: 144.91 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $144.91 | 52 Week High | $65.46 | |||
| Open | $144.91 | 52 Week Low | $47.97 | |||
| Day High | $144.91 | P/E | 98.58 | |||
| Day Low | $144.91 | EPS | $1.47 | |||
| Volume | 1,204 | |||||
